Annual Report, Notice of AGM and Board Change

Apr 29, 2022

Advanced Medical Solutions Group plc
(“AMS” or the “Group”)

RNS Number : 9541J
Advanced Medical Solutions Grp PLC
29 April 2022

Advanced Medical Solutions Group plc

(“AMS” or the “Group”)


Annual Report, Notice of Annual General Meeting and Board Change


Winsford, UK – 29 April 2022: Advanced Medical Solutions Group plc (AIM: AMS), the world-leading specialist in tissue-healing technologies, announces that the Annual Report and Accounts for the year ended 31 December 2021 and Notice of Annual General Meeting were posted to shareholders today and are available on the Investor Relations section of the Group’s website.


Annual General Meeting


The Board continues to monitor the COVID-19 pandemic and our priority at this time remains the health, safety and wellbeing of all of our stakeholders. We are delighted that, at the time of issuing this Notice, we will be able to hold the AGM with no COVID-19 restrictions. However, the Board recognises that the COVID-19 pandemic is an evolving situation and that it may be necessary to modify our AGM arrangements. The arrangements are therefore subject to change, including at short notice, if circumstances and/or public health guidance changes.


The Board therefore recommends that you monitor the Company’s announcements for any updates and register to receive our RNS alerts at investor-relations/alert-service.


The Notice of Annual General Meeting and proxy forms were posted to shareholders today and are available on the Group’s website at The AGM will be convened with the minimum necessary quorum of two shareholders. The outcome of the resolutions will as usual be determined by shareholder vote based on the proxy votes received.


Shareholders are strongly encouraged to vote by proxy on the resolutions contained in the AGM Notice and to appoint the “Chairman of the Meeting” as their proxy, providing instructions on how the Chair should vote on the proposed resolutions. This will ensure that your votes will be counted if you (or any other proxy who you might otherwise appoint) choose not to attend the AGM in person.


To ensure votes are counted at the AGM, completed proxy forms should be returned to: Link Group, PXS, 10th Floor, Central Square, 29 Wellington Street, Leeds, LS1 4DL and must be received by 11:00 am on 6 June 2022 in order to be valid. This is particularly important given potential delays due to the continued impact of COVID-19, which could potentially cause delays to the collection and delivery of postal services. Any shareholder who wishes to attend the AGM in person is asked to register their intention to do so as soon as practicable.


The results of the AGM will be announced to the London Stock Exchange and placed on the Group’s website, in the usual way, as soon as practicable after the conclusion of the AGM.


Non-Executive Board Refreshment


As reported previously, in accordance with the 2018 UK Corporate Governance Code the Group is implementing a plan to refresh the Non-Executive members of its Board, which began in 2020 and is expected to complete in 2023.


Having appointed Grahame Cook and Douglas Le Fort as Non-Executive Directors in 2021, Penny Freer is due to retire from the Board at the upcoming AGM. It is expected that Douglas Le Fort will become Chair of the Remuneration Committee, having worked closely with Penny since he joined the Remuneration Committee in 2021. The Board would like to thank Penny for her significant contribution to the success of AMS over the last twelve years.


– End –

For further information, please contact:

Advanced Medical Solutions Group plc

Tel: 44 (0) 1606 545508

Chris Meredith, Chief Executive Officer

Eddie Johnson, Chief Financial Officer

Michael King, Investor Relations

Consilium Strategic Communications

Tel: 44 (0) 20 3709 5700

Matthew Neal / Lucy Featherstone

Investec Bank PLC (NOMAD & Broker)

Tel: 44 (0) 20 7597 5970

Gary Clarence / David Anderson

HSBC Bank PLC (Broker)

Tel: 44 (0) 20 7991 8888

Sam McLennan / Joe Weaving / Stephanie Cornish

About Advanced Medical Solutions Group plc

AMS is a world-leading independent developer and manufacturer of innovative tissue-healing technology, focused on quality outcomes for patients and value for payers. AMS has a wide range of surgical products including tissue adhesives, sutures, haemostats, internal fixation devices and internal sealants, which it markets under its brands LiquiBand®, RESORBA®, LiquiBandFix8® and Seal-G®. AMS also supplies wound care dressings such as silver alginates, alginates and foams through its ActivHeal® brand as well as under white label. Since 2019, the Group has made five acquisitions: Sealantis, an Israeli developer of innovative internal sealants; Biomatlante, a French developer and manufacturer of surgical biomaterials, Raleigh, a leading UK coater and converter of woundcare and bio-diagnostics materials, AFS Medical, an Austrian specialist surgical business and Connexicon, an Irish tissue adhesives specialist.

AMS's products, manufactured in the UK, Germany, France, the Netherlands, the Czech Republic and Israel, are sold globally via a network of multinational or regional partners and distributors, as well as via AMS's own direct sales forces in the UK, Germany, Austria, the Czech Republic and Russia. The Group has R&D innovation hubs in the UK, Ireland, Germany, France and Israel. Established in 1991, the Group has more than 800 employees. For more information, please see

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.